Samsung Biologics Co Ltd
KRX:207940

Watchlist Manager
Samsung Biologics Co Ltd Logo
Samsung Biologics Co Ltd
KRX:207940
Watchlist
Price: 938 000 KRW -1.16%
Market Cap: 66.8T KRW
Have any thoughts about
Samsung Biologics Co Ltd?
Write Note

Samsung Biologics Co Ltd
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Samsung Biologics Co Ltd
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
Samsung Biologics Co Ltd
KRX:207940
Note Receivable
â‚©309.3B
CAGR 3-Years
16%
CAGR 5-Years
26%
CAGR 10-Years
N/A
K
Knotus Co Ltd
KOSDAQ:278650
Note Receivable
â‚©970m
CAGR 3-Years
6%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
S
ST Pharm Co Ltd
KOSDAQ:237690
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Note Receivable
â‚©2.2B
CAGR 3-Years
63%
CAGR 5-Years
45%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Note Receivable
â‚©98.1m
CAGR 3-Years
N/A
CAGR 5-Years
0%
CAGR 10-Years
N/A
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Note Receivable
â‚©1.5k
CAGR 3-Years
-98%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Samsung Biologics Co Ltd
Glance View

Market Cap
66.8T KRW
Industry
Life Sciences Tools & Services

In the bustling world of biopharmaceuticals, Samsung Biologics Co Ltd has carved a niche as a formidable player, merging cutting-edge technology with industrial scale to drive its operations. Situated in Incheon, South Korea, the company emerged as a key subsidiary of Samsung Group, bringing with it the organizational prowess and strategic vision that hallmark the conglomerate. Established with the goal of reshaping the global landscape of biopharmaceutical manufacturing, Samsung Biologics offers a suite of contract development and manufacturing organization (CDMO) services. From early-stage development to large-scale production, the company supports clients through every step of a biologic's lifecycle, ensuring seamless transition from laboratory to patient. The blend of state-of-the-art facilities and advanced process technologies enables them to meet the growing demands for complex biopharmaceuticals efficiently. Samsung Biologics' revenue machine spins around its comprehensive service spectrum, which includes drug substance and product manufacturing and laboratory testing services. The contract-based model allows global pharma companies to outsource crucial parts of their development and manufacturing processes to Samsung Biologics, thus optimizing costs and timelines. By building strategic partnerships and continuously investing in expanding its manufacturing capacity, Samsung Biologics not only captures market share but also aligns itself with the burgeoning demand for biosimilars and other next-generation therapeutics. Furthermore, operating within a highly regulated and competitive industry, the company's focus on maintaining stringent quality standards and regulatory compliance cements its reputation as a trusted partner in the pharmaceutical sector.

Intrinsic Value
490 513.26 KRW
Overvaluation 48%
Intrinsic Value
Price

See Also

What is Samsung Biologics Co Ltd's Note Receivable?
Note Receivable
309.3B KRW

Based on the financial report for Sep 30, 2024, Samsung Biologics Co Ltd's Note Receivable amounts to 309.3B KRW.

What is Samsung Biologics Co Ltd's Note Receivable growth rate?
Note Receivable CAGR 5Y
26%

Over the last year, the Note Receivable growth was 31%. The average annual Note Receivable growth rates for Samsung Biologics Co Ltd have been 16% over the past three years , 26% over the past five years .

Back to Top